{"organizations": [], "uuid": "4420b4694f7c3f749c629ae083b619b0e7075afa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-karyopharm-announces-agreement-for/brief-karyopharm-announces-agreement-for-biogen-to-acquire-kpt-350-idUSASB0C2A7", "country": "US", "domain_rank": 408, "title": "BRIEF-Karyopharm Announces Agreement For Biogen To Acquire KPT-350", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.133, "site_type": "news", "published": "2018-01-25T19:35:00.000+02:00", "replies_count": 0, "uuid": "4420b4694f7c3f749c629ae083b619b0e7075afa"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-karyopharm-announces-agreement-for/brief-karyopharm-announces-agreement-for-biogen-to-acquire-kpt-350-idUSASB0C2A7", "ord_in_thread": 0, "title": "BRIEF-Karyopharm Announces Agreement For Biogen To Acquire KPT-350", "locations": [], "entities": {"persons": [], "locations": [{"name": "karyopharm", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "karyopharm therapeutics inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "karyopharm therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Karyopharm Therapeutics Inc:\n* KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS\n* KARYOPHARM THERAPEUTICS INC - DEAL VALUED AT UP TO $217 MILLION\n* KARYOPHARM THERAPEUTICS - ‚ÄçBIOGEN IS ACQUIRING KPT-350 AND OTHER ASSETS TARGETING CERTAIN NEUROLOGICAL CONDITIONS, INCLUDING ALS\n* KARYOPHARM - DEAL INCLUDES $10 MILLION UPFRONT PAYMENT TO KARYOPHARM, AND POTENTIAL $207 MILLION IN FUTURE MILESTONES, PLUS ROYALTIES\n* KARYOPHARM - CO ALSO ELIGIBLE TO GET TIERED ROYALTIES FROM BIOGEN THAT REACH LOW DOUBLE DIGITS BASED ON FUTURE NET SALES OF SOME PRODUCT CANDIDATES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T19:35:00.000+02:00", "crawled": "2018-01-26T21:29:00.003+02:00", "highlightTitle": ""}